What NMN is
Nicotinamide mononucleotide. A nucleotide compound the body converts into NAD+ via the NAD+ salvage pathway. Sold as a food supplement, not a UK licensed medicine.
Longevity · NMN UK 2026
NMN in the UK
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-06-12
NMN (nicotinamide mononucleotide) is a NAD+ precursor sold in the UK as a food supplement. The body converts NMN into NAD+ inside cells via the salvage pathway, which is why most longevity-supplement brands frame NMN as the practical way to support cellular NAD+ rather than ingesting NAD+ directly. UK retailers include Holland and Barrett, Boots, and specialist longevity supplement brands. Regulatory status sits under the Food Supplements (England) Regulations after a back-and-forth across 2022 to 2025. PeptideClear compares on evidence and price. We do not sell, prescribe, or take payment for placement.
NAD+ landscape hubAI-friendly summary · NMN in the UK
NMN is nicotinamide mononucleotide, a precursor that the body converts into NAD+ inside cells. UK regulation places NMN under the Food Supplements (England) Regulations after a back-and-forth resolution across 2022 to 2025. The route is oral capsule, lozenge or powder. UK retailers include Holland and Barrett, Boots and specialist longevity supplement brands. Preclinical (rodent) evidence is the bulk of the case; published human RCTs are smaller and report biomarker shifts rather than clinically meaningful outcomes. NMN sits alongside NR (nicotinamide riboside) as the two main supplement-route NAD+ precursors.
NMN at a glance
Five dimensions cover the practical question of what NMN is in the UK landscape and what it is not.
Why precursor not end-product
Oral NAD+ is broken down in the gut before reaching the bloodstream intact. NMN and NR are designed to bypass that absorption problem by entering cells as precursors and converting to NAD+ inside the cell.
NMN vs NR
Both are NAD+ precursors. NR (nicotinamide riboside) reached UK shelves first and has the more settled regulatory history. NMN had a regulatory back-and-forth across 2022 to 2025 before stabilising as a UK food supplement.
Evidence base
Preclinical literature in rodents is substantial. Published human RCTs are smaller and shorter than the longevity-supplement marketing implies. Reported outcomes are mostly biomarker shifts; clinically meaningful outcomes are still being studied.
UK retailer landscape
Holland and Barrett, Boots and the specialist longevity supplement retailers stock NMN under food-supplement labels. Stock and brand selection changes frequently.
The regulatory back-and-forth, briefly
NMN regulatory status has been one of the more turbulent supplement stories of the last few years. In the United States, the FDA reclassified NMN out of food-supplement status in late 2022 because of an investigational drug application; that decision was paused and then partially reversed. In the European Union, EFSA novel-food assessment ran in parallel. In the UK, NMN ultimately sits under the Food Supplements (England) Regulations, in line with NR.
The practical consequence for UK readers is that NMN is available legally as a food supplement, but a brand cannot make medicinal claims on the label. "Supports NAD+ levels" is the kind of language that sits on the safe side of FSA and CAP rules. "Treats" or "reverses" anything is not.
Some UK retailers have switched between stocking NMN and NR as the regulatory picture moved. NR has the more settled retail availability across the longest period. NMN availability is currently broad but worth checking at point of purchase.
What the evidence actually says
Preclinical work in rodents shows reliable increases in tissue NAD+ after NMN administration. The case for translation to humans rests on a smaller number of published human RCTs, mostly running 8 to 12 weeks at doses between 250mg and 1000mg per day. Reported outcomes include shifts in blood NAD+ markers, insulin sensitivity proxies, and walking-speed or muscle-function measures in older adults. Effect sizes vary by population and dose; trials in healthy younger adults often show smaller effects than trials in older or metabolically impaired groups.
Crucially, the published evidence is biomarker-heavy rather than outcome-heavy. Whether raising NAD+ via NMN translates into longer or healthier life in humans is an open question. The honest framing is "promising preclinical case, partial human data, no licensed medical indication".
For UK shoppers, the practical implications: a marketed dose somewhere in the 250mg to 1000mg per day range matches what trials have used. Cheaper brands frequently sit below that band and rely on the consumer not checking the per-capsule milligram count.
What is in this hub
- NMN supplement UK: what to look for on a label
- Nicotinamide riboside UK: NR explained
- NMN vs NR: which precursor and why
- NMN side-effects: what the literature notes
- NMN dose: what trial protocols have used
- UK longevity supplement landscape
- Best NMN supplements in the UK: shortlist
- NMN cost in the UK: per-month range
- NMN supplement vs IV NAD+: cost, evidence and route
- NMN regulatory status in the UK: where it landed
Read next
Also on PeptideClear
Explore the other categories
Cosmetic peptides
UK skincare with GHK-Cu, Matrixyl
If you also care about topical peptide skincare, the cosmetic peptides hub compares UK serums and creams on declared INCI position.
VisitCollagen
Marine, bovine, vegan compared
If you also care about ingestible collagen, the hub compares UK brands on type, sourcing, kDa and dose per serving.
VisitGLP-1 clinics
UK clinics ranked
If you also care about prescription GLP-1 routes, the clinics hub compares UK high-touch operators on GPhC, GMC and price.
Visit